vTv Therapeutics (FRA:5VT0) Cyclically Adjusted FCF per Share: €-53.37 (As of Mar. 2026)


FRA:5VT0 vTv Therapeutics Inc FRA:5VT0
35 GF Score
Price €29.20
GF Value €6,624.85
View Full Analysis

What is vTv Therapeutics Cyclically Adjusted FCF per Share?

vTv Therapeutics FRA:5VT0 -0.68% 35 Cyclically Adjusted FCF per Share is €-53.37 as of Mar. 2026. GuruFocus rates FRA:5VT0 with a GF Score™ of 35/100 and a GF Value™ of €6,624.85.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

vTv Therapeutics's adjusted free cash flow per share for the three months ended in Mar. 2026 was €0.541. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is €-53.37 for the trailing ten years ended in Mar. 2026.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

As of today (2026-07-09), vTv Therapeutics's current stock price is €29.20. vTv Therapeutics's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2026 was €-53.37. vTv Therapeutics's Cyclically Adjusted Price-to-FCF of today is .


vTv Therapeutics  (FRA:5VT0) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


vTv Therapeutics Cyclically Adjusted FCF per Share Related Terms


vTv Therapeutics Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for vTv Therapeutics's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

vTv Therapeutics Cyclically Adjusted FCF per Share Chart

vTv Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 -89.22 -81.18 -57.77

vTv Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -82.75 -69.61 -65.03 -57.77 -53.37

FRA:5VT0 vs SMNR, CNTB, ENLV: Cyclically Adjusted FCF per Share Comparison

For the Biotechnology subindustry, vTv Therapeutics's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


vTv Therapeutics Cyclically Adjusted Price-to-FCF vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, vTv Therapeutics's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where vTv Therapeutics's Cyclically Adjusted Price-to-FCF falls into.


FRA:5VT0
35GF Score
vTv Therapeutics Inc FRA:5VT0
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

vTv Therapeutics Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, vTv Therapeutics's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=0.541/330.2130*330.2130
=0.541

Current CPI (Mar. 2026) = 330.2130.

vTv Therapeutics Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201606 -43.021 241.018 -58.942
201609 -46.864 241.428 -64.098
201612 -44.760 241.432 -61.219
201703 -53.529 243.801 -72.502
201706 -46.475 244.955 -62.651
201709 -40.826 246.819 -54.620
201712 -22.107 246.524 -29.612
201803 -18.087 249.554 -23.933
201806 -31.817 251.989 -41.694
201809 -17.419 252.439 -22.786
201812 -11.672 251.233 -15.341
201903 -8.432 254.202 -10.953
201906 -6.940 256.143 -8.947
201909 -7.005 256.759 -9.009
201912 -5.560 256.974 -7.145
202003 -4.629 258.115 -5.922
202006 -3.728 257.797 -4.775
202009 -3.825 260.280 -4.853
202012 -1.421 260.474 -1.801
202103 -3.152 264.877 -3.929
202106 -2.265 271.696 -2.753
202109 -2.001 274.310 -2.409
202112 -3.053 278.802 -3.616
202203 -0.554 287.504 -0.636
202206 0.380 296.311 0.423
202209 -4.431 296.808 -4.930
202212 -2.913 296.797 -3.241
202303 -2.314 301.836 -2.532
202306 -2.730 305.109 -2.955
202309 -2.172 307.789 -2.330
202312 -1.282 306.746 -1.380
202403 -1.630 312.332 -1.723
202406 -0.976 314.175 -1.026
202409 -1.060 315.301 -1.110
202412 -0.699 315.605 -0.731
202503 -0.799 319.799 -0.825
202506 -0.671 322.561 -0.687
202509 -0.552 324.800 -0.561
202512 -0.634 324.054 -0.646
202603 0.541 330.213 0.541

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of €-53.37 mean?
vTv Therapeutics (FRA:5VT0) has a Cyclically Adjusted FCF per Share of €-53.37 as of Mar. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on vTv Therapeutics and its competitors.
Is vTv Therapeutics' Cyclically Adjusted FCF per Share too high?
vTv Therapeutics' current Cyclically Adjusted FCF per Share is €-53.37. Overall, vTv Therapeutics has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does vTv Therapeutics' Cyclically Adjusted FCF per Share compare to SMNR and CNTB?
vTv Therapeutics' Cyclically Adjusted FCF per Share of €-53.37 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Biotechnology company?
A good Cyclically Adjusted FCF per Share depends on the Biotechnology industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on vTv Therapeutics and its competitors. vTv Therapeutics's current Cyclically Adjusted FCF per Share is €-53.37. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is vTv Therapeutics stock overvalued right now?
vTv Therapeutics (FRA:5VT0) has a current Cyclically Adjusted FCF per Share of €-53.37. The stock's GF Value™ is €6,624.85, compared to a current price of €29.20 — trading 99.6% below its estimated fair value. The current Cyclically Adjusted FCF per Share is €-53.37. vTv Therapeutics' overall GF Score™ is 35/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For vTv Therapeutics (FRA:5VT0), the current Cyclically Adjusted FCF per Share is €-53.37 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is vTv Therapeutics (FRA:5VT0) Overvalued in 2026?

Based on GuruFocus' analysis, vTv Therapeutics stock appears to be undervalued. The current stock price of €29.20 is trading 99.6% below its estimated GF Value™ of €6,624.85.

Key valuation signals for FRA:5VT0:

  • Cyclically Adjusted FCF per Share: €-53.37
  • GF Value™: €6,624.85 vs. price of €29.20 (99.6% below fair value)
  • GF Score™: 35/100

No single metric tells the full story. See the FRA:5VT0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


vTv Therapeutics Business Description

Other Exchanges VTVT:USA
Address 3980 Premier Drive, Suite 110, High Point, NC, USA, 27265
vTv Therapeutics Inc is a late-stage biopharmaceutical company focused on developing oral, small-molecule drug candidates intended to help treat people living with diabetes and other chronic diseases. Its clinical pipeline is led by cadisegliatin (TTP399), a novel, small-molecule, liver-selective glucokinase activator (GKA) currently being evaluated as a potential oral adjunctive therapy to insulin for the treatment of type 1 diabetes (T1D). In addition, the company is also engaged in the research and development of other candidates in its pipeline through collaborations with academic partners and license agreements, which include TTP273, HPP737, TTP-RA, Mavodelpar (HPP593), HPP971, and HPP3033, being studied and developed to counter various chronic diseases.
35GF Score

Get the complete analysis for FRA:5VT0

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€29.20
Price
€6,624.85
GF Value